Pharmaceuticals News and Research

RSS

Solasia Pharma completes Phase I clinical trial for Sancuso extended release transdermal granisetron patch

Solasia Pharma K.K. (http://www.solasia.co.jp), a developer of Western oncology pharmaceuticals in-licensed for commercialization in Asian markets, announced today the completion of a Phase I clinical trial for SP-01 (extended release transdermal granisetron patch; brand name: Sancuso®) in Japanese volunteers.

30 Oct 2009

China Medicine announces acquisition of Guangzhou LifeTech Pharmaceuticals

China Medicine Corporation, a developer and leading distributor of prescription and over-the-counter pharmaceuticals, traditional Chinese medicines ("TCM"), nutritional and dietary supplements, and medical devices and medical formulations, today announced that through its wholly-owned subsidiary in China, Konzern Pharmaceuticals, it has signed an equity transfer agreement (the "Transfer Agreement") to acquire 100% of equity interests in Sinoform Limited.

30 Oct 2009

Health industry stakeholders focus on pain, not gain

Businesses, including medical device makers, insurers and pharmaceutical companies are bracing for tax and fee provisions in the House health care reform bill.

30 Oct 2009

Impax Laboratories initiates patent challenge for TRICOR

Impax Laboratories, Inc. today confirms that it has initiated a challenge of the patents listed by Abbott Laboratories in connection with its TRICOR® (fenofibrate) tablets, 48 mg and 145 mg.

30 Oct 2009

Bayer HealthCare's Phase II study results of imaging agent florbetaben

Bayer HealthCare presented results from a global Phase II study of florbetaben, its imaging agent in development for the detection of cerebral beta-Amyloid plaques, at the 19th World Congress of Neurology (WCN).

30 Oct 2009

NeoStem completes acquisition of China Biopharmaceuticals Holdings

NeoStem, Inc., announced today that the Company has completed the acquisition of China Biopharmaceuticals Holdings, Inc., a leading Chinese pharmaceutical company.

30 Oct 2009

P&G's global branded prescription pharmaceutical business acquired by Warner Chilcott

Warner Chilcott plc announced today it has completed the acquisition of The Procter & Gamble Company's global branded prescription pharmaceutical business. The acquisition complements Warner Chilcott's existing presence in women's health care and adds new therapeutic and geographic markets.

30 Oct 2009

VIA Pharmaceuticals to discuss its cardio-metabolic product portfolio at the Target 2009 conference

VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic diseases, today announced that Dr. Rebecca Taub, Senior Vice President Research & Development will present "Liver Directed Beta Agonist for Targeting Cardiometabolic Disease", and will discuss the Company's cardio-metabolic product portfolio, including VIA's inhibitor of 5 Lipoxygenase, its THR Beta Agonist, and its DGAT1 development programs, at the Cambridge Healthtech Institute Seventh International Discovery on Target 2009 program, on November 3, 2009 in Boston, MA.

30 Oct 2009

Sunesis Pharmaceuticals enrolls 113 patients in voreloxin REVEAL-1 trial

Sunesis Pharmaceuticals, Inc. today reported that it has completed enrollment in the REVEAL-1 (Response Evaluation of VorEloxin in AmL) trial, a Phase 2 dose regimen optimization trial of single agent voreloxin in newly diagnosed elderly acute myeloid leukemia (AML) patients who are unlikely to benefit from standard induction chemotherapy. A total of 113 patients were enrolled and dosed according to one of three dosing schedules.

30 Oct 2009

CCBR-SYNARC to expand its Electronic Data Capture capabilities for use in imaging clinical trials

CCBR-SYNARC, the world's leading provider of medical image analysis, biochemical marker, and clinical research center services to the pharmaceutical and biotechnology industries, announced the expansion of its Electronic Data Capture ("EDC") capabilities for use in imaging clinical trials.

30 Oct 2009

Idenix Pharmaceuticals reports phase I study results of IDX184 for treating HCV

Idenix Pharmaceuticals, Inc.a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced presentations of data on IDX184, a once-daily novel liver-targeted nucleotide prodrug of 2'-methyl guanosine (2'MeG) for the treatment of HCV, at the annual meeting of the American Association for the Study of Liver Diseases (AASLD) currently being held in Boston, Massachusetts.

30 Oct 2009

Valeant Pharmaceuticals to acquire prescription and cosmetic products rights from Polish

Valeant Pharmaceuticals International (NYSE: VRX) today announced that it has agreed to acquire the rights to several prescription and cosmetic dermatology products from a privately-held, Polish specialty pharmaceutical company.

30 Oct 2009

PMSI Holdings to purchase rights under the patent portfolio held by Ronald A. Katz Technology Licensing

Ronald A. Katz Technology Licensing, L.P. announced today that PMSI Holdings Corporation, one of the world's largest pharmaceutical services companies serving the United States with headquarters in Tampa, FL, has entered into an agreement to purchase rights under the patent portfolio held by Ronald A. Katz Technology Licensing, L.P. and licensed through its affiliate, A2D, L.P.

30 Oct 2009

AcelRx Pharmaceuticals completes End-of-Phase 2 meeting with the FDA for its ARX-01drug/device

AcelRx Pharmaceuticals, Inc. today announced that it has successfully completed an End-of-Phase 2 meeting with the FDA for ARX-01, a drug/device combination product based on the company's proprietary NanoTab(TM) dosage form, which enables delivery of sufentanil by the non-invasive oral transmucosal (sublingual) route.

30 Oct 2009

Mintel predicts increased sales of OTC drugs in upcoming months

Autumn has arrived in the northern hemisphere and with shades of yellow and orange comes a less-welcome visitor: cold and flu season. Made worse this year by the H1N1 (swine flu) pandemic, people around the world are flocking to drugstores and supermarkets to stock up on over-the-counter (OTC) medicine, says market research firm Mintel.

30 Oct 2009

Clinical data on the validation set 'Alzheimer patients versus healthy controls' for AclarusDx presented

ExonHit Therapeutics yesterday presented clinical data on the validation set “Alzheimer patients versus healthy controls” for AclarusDx™ (formerly EHT Dx21), its blood-based diagnostic test for the detection of Alzheimer’s disease (AD), at the 2nd Conference of Clinical Trials on Alzheimer’s Disease (CTAD) in Las Vegas, USA.

30 Oct 2009

ARYx Therapeutics to complete an out-licensing agreement for clinical development and commercialization of budiodarone

ARYx Therapeutics, Inc., a biopharmaceutical company, today announced that it has implemented a staffing plan to operate the company that anticipates licensing its lead development programs and resuming development of earlier stage product candidates.

30 Oct 2009

Shire's ADHD treatment data to be presented at the Honolulu psychiatric meeting

Shire plc, the global specialty biopharmaceutical company, announced today that it will present key scientific data on its Attention-Deficit/Hyperactivity Disorder (ADHD) treatments, INTUNIV(TM) (guanfacine) Extended Release Tablets, Vyvanse®( ) (lisdexamfetamine dimesylate) Capsules CII, and Daytrana®( ) (methylphenidate transdermal system) CII, at a national meeting of psychiatrists to be held October 27 - November 1 in Honolulu.

30 Oct 2009

New state-of-the-art biotechnology center opened on the West Coast

As part of its strategy to discover and develop more biotechnology medicines, Eli Lilly and Company today officially opened a new state-of-the-art biotechnology center on the West Coast.

30 Oct 2009

UCSF scientists receive grants to advance stem cell based strategies for diabetes and brain tumors

Two teams of UCSF scientists have received grants from the California Institute for Regenerative Medicine to advance their stem cell based strategies for treating diabetes and brain tumors.

30 Oct 2009

Pharmaceuticals News and Research

Solasia Pharma completes Phase I clinical trial for Sancuso extended release transdermal granisetron patch

China Medicine announces acquisition of Guangzhou LifeTech Pharmaceuticals

Health industry stakeholders focus on pain, not gain

Impax Laboratories initiates patent challenge for TRICOR

Bayer HealthCare's Phase II study results of imaging agent florbetaben

NeoStem completes acquisition of China Biopharmaceuticals Holdings

P&G's global branded prescription pharmaceutical business acquired by Warner Chilcott

VIA Pharmaceuticals to discuss its cardio-metabolic product portfolio at the Target 2009 conference

Sunesis Pharmaceuticals enrolls 113 patients in voreloxin REVEAL-1 trial

CCBR-SYNARC to expand its Electronic Data Capture capabilities for use in imaging clinical trials

Idenix Pharmaceuticals reports phase I study results of IDX184 for treating HCV

Valeant Pharmaceuticals to acquire prescription and cosmetic products rights from Polish

PMSI Holdings to purchase rights under the patent portfolio held by Ronald A. Katz Technology Licensing

AcelRx Pharmaceuticals completes End-of-Phase 2 meeting with the FDA for its ARX-01drug/device

Mintel predicts increased sales of OTC drugs in upcoming months

Clinical data on the validation set 'Alzheimer patients versus healthy controls' for AclarusDx presented

ARYx Therapeutics to complete an out-licensing agreement for clinical development and commercialization of budiodarone

Shire's ADHD treatment data to be presented at the Honolulu psychiatric meeting

New state-of-the-art biotechnology center opened on the West Coast

UCSF scientists receive grants to advance stem cell based strategies for diabetes and brain tumors

Ultimate guide to the essential tools for the characterization of proteins, polymers and nanoparticles eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring